Allogene: Positive results from early CAR[T lymphoma candidate

 

• ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL)
  

  • Overall Response Rate (ORR) of 75% and CR Rate of 50% Across Histologies in CAR T Naïve Patients, on Par with Data from Pivotal Trials of Autologous CAR T Therapies

  • Six Month CR Rate of 36% with One Time Treatment in CAR T Naïve Patients with LBCL

  • 98% of Enrolled Patients Received ALLO-501 With a Median Time of 5 Days from Enrollment to Start of Therapy

• Interim Phase 1 ALPHA2 Data Demonstrated a Comparable Efficacy and Safety Profile for ALLO-501A Relative to ALLO-501

• Consolidation Dosing was Well Tolerated and Shows Early Promise with Four Patients Converting from Partial Response (PR) to CR Following Second Dose of ALLO-501 or ALLO-501A

• No Dose Limiting Toxicities or Graft-vs-Host Disease; Limited Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Cytokine Release Syndrome (CRS)

• Safety and PK/PD Data of ALLO-647 with Flu/Cy Across ALPHA, ALPHA2 and UNIVERSAL (ALLO-715 in Multiple Myeloma) Trials Demonstrated Manageable Safety Profile; Exposure-Dependent Deep Lymphodepletion Correlated with AlloCAR T Cell Expansion and Clinical Responses

• Initiation of Pivotal Trial of ALLO-501A Planned for Late 2021

• Two Posters to be Presented at the Annual Meeting of the American Society of Clinical Oncology on June 4, 2021 on ALLO-501, ALLO-501A and ALLO-647

• Company to Host May 19 Virtual CD19 Forum at 5:30 PM Eastern Time

SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during today’s virtual CD19 Forum. The Forum will include results from Phase 1 ALPHA (ALLO-501) and ALPHA2 (ALLO-501A) trials in relapsed/refractory non-Hodgkin lymphoma (NHL), developed in collaboration with Servier, as well as safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from ALLO-647. ALLO-647 is part of the Company’s differentiated lymphodepletion regimen. The Forum will also discuss the Company’s approach for optimizing the unique benefits of its allogeneic CAR T therapy platform and the potential role of AlloCAR T therapy in NHL based upon views from clinical trial investigators and early market research.

https://finance.yahoo.com/news/allogene-therapeutics-cd19-forum-highlights-205100749.html